



#42/4  
9/4/98  
C.Syle

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

COATES et al.

Examiner: J. Ford

Serial No.: 07/835,964

Group Art Unit: 1611

Filed: February 20, 1992

For: 1,3-OXATHIOLANE NUCLEOSIDE ANALOGUES

98 AUG -5 AM 1:25  
GROUP 180  
RECORDED

**SUPPLEMENTAL AMENDMENT**

Assistant Commissioner for Patents  
Washington, DC 20231

SIR:

Further to the Amendment of July 7, 1998, please amend the above-identified application as follows:

**IN THE CLAIMS:**

Please cancel claims 7 and 24.

Please amend claims 23, 25 and 26 as follows:

~~23. (Amend) A method for treating a mammal suffering from HIV infection comprising: [the step of]~~

~~administering to said mammal [a patient suffering from that infection] a pharmaceutical[ly] composition comprising 10-1500 mg [effective amount] of the compound (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one and a pharmaceutically acceptable carrier, [substantially free of the corresponding (+) enantiomer, the treatment bein associated with a lower cytotoxicity than treatment using the corresponding (+) enantiomer of a racemic mixture of the two enantiomers.]~~

~~25. (Amended) A method for treating a mammal suffering from HIV infection comprising administering to said mammal a pharmaceutical composition comprising: [a pharmaceutically acceptable carrier,] the compound (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, and a pharmaceutically acceptable carrier.~~